Core Viewpoint - The stock of Meihao Medical (301363) has shown fluctuations in trading performance, with a recent closing price of 20.83 yuan, reflecting a 2.51% increase on November 24, 2025, amidst varying capital flows [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main business revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decline of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main business revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.9 million yuan, an increase of 5.89% year-on-year [3]. Capital Flow Analysis - On November 24, 2025, the net outflow of main funds was 4.29 million yuan, accounting for 4.82% of the total transaction amount, while retail investors saw a net inflow of 9.61 million yuan, representing 10.78% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced varying capital flows, with significant net outflows from main and speculative funds on several days [2]. Industry Comparison - Meihao Medical's total market value stands at 11.85 billion yuan, slightly above the industry average of 10.978 billion yuan, ranking 25th out of 124 in the medical device sector [3]. - The company's price-to-earnings ratio (P/E) is 42.69, which is lower than the industry average of 55.96, ranking 50th in the industry [3]. Analyst Ratings - In the last 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating a generally positive outlook [4].
股票行情快报：美好医疗（301363）11月24日主力资金净卖出429.16万元